semaj83/ctmatch_classification huggingface dataset:
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Congenital Diaphragmatic Hernia Patient is a pregnant woman between 18 and 45 years of age Singleton pregnancy The fetuses will be 28+0/7 to 31+6/7 weeks of gestational age Confirmed diagnosis of severe left or right-sided CDH of the fetus: Observed/expected total lung volume equal to or less than 0.32 with more than 21% of liver herniated into the hemithorax. (Ideally calculated between 28+0/7 and 31+6/7 weeks' gestation.) Normal fetal echocardiogram or echocardiogram with a minor anomaly (such a small VSD) that in the opinion of the pediatric cardiologist will not affect postnatal outcome Normal fetal karyotype or microarray The mother must be healthy enough to have surgery Patient and father of the baby provide signed informed consent that details the maternal and fetal risks involved with the procedure Patient willing to remain in Houston for the duration following balloon placement until delivery  Contraindication to abdominal surgery, fetoscopic surgery, or general anesthesia Allergy to latex Allergy or previous adverse reaction to a study medication specified in this protocol Preterm labor, preeclampsia, or uterine anomaly (e.g., large fibroid tumor) in the index pregnancy Fetal aneuploidy, known structural genomic variants, other major fetal anomalies that may impact the fetal/neonatal survival or known syndromic mutation Suspicion of major recognized syndrome (e.g. Fryns syndrome) on ultrasound or MRI Maternal BMI >40 High risk for fetal hemophilia
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 21.0-40.0,  Polycystic Ovary Syndrome We will women in one PCOS subtype, those having these two symptoms Hyperandrogenism (a) If not on current birth control: hyperandrogenism defined as current elevated total testosterone >= 50 ng/dL or free androgen index > 1.5 (ratio of testosterone/SHBG x 100) or severe acne or hirsutism (b) if on current birth control: history from the past 10 years of hyperandrogenism defined as past elevated total testosterone >= 50 ng/dL or free androgen index > 1.5 (ratio of testosterone/SHBG x 100) or severe acne or hirsutism oligomenorrhea-anovulation defined as spontaneous intermenstrual periods of ≥ 45 days or a total of ≤ 8 menses per year. Participants must also be overweight or obese (BMI 25-50) be 21-40 years old have regular access to the internet be able to engage in light physical activity willing and able to follow the assigned intervention  a non-English speaker inability to complete baseline measurements a substance abuse, mental health, or medical condition that would interfere with participation (such as current chemotherapy) pregnant or planning to get pregnant in the next 6 months type 1 or type 2 diabetes baseline aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 times normal baseline renal disease defined as BUN > 30 mg/dL or serum creatinine >1.4 mg/dL baseline uncorrected thyroid disease (TSH <0.45 mIU/ML or >4.5 mIU/ML) breastfeeding or less than 6 months post-partum planned or history of weight loss surgery
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Colorectal Cancer Patients with age more than 18 years Presenting to fast track colorectal clinic 1. With bowel symptoms 2. Presenting with anaemia 3. Rectal bleeding  Any patient presenting through routine colorectal clinics 1. With bowel symptoms 2. Presenting with anaemia 3. Rectal bleeding Aged less than 18 years
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 18.0-89.0,  Propionibacterium Acnes Male subjects Subjects scheduled for elective shoulder arthroplasty at the University of Washington Medical Center Subjects between ages 18-89  Subjects who self-report very sensitive skin Subjects who are sensitive to benzoyl peroxide Subjects who are allergic to chlorhexidine Subjects who had recent prior use of antibiotics (or expect to use them prior to surgery) Subjects who had recent use of acne treatment Subjects who are not fluent in English
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lung Cancer Non Small Cell Lung Cancer Adenocarcinoma of Lung Participants are eligible to be included in the study only if all of the following apply Male and female participants who are at least 18 years of age on the day of signing the informed consent will be enrolled in the study Subjects must have histologically confirmed diagnosis of non-squamous non-small cell lung cancer not amenable to potentially curative treatments (surgical resection, definitive radiation therapy or a combined modality approach) or targeted agents to actionable EGFR mutations or ALK or ROS1 gene rearrangement and excluding neuroendocrine tumors. Activating KRAS mutations are allowed. The diagnosis must be confirmed by the Laboratory of Pathology, CCR, NCI. Mutation confirmation may be done by referring institutions or by one of the assays in the Protocol Have provided archival tumor tissue sample or newly obtained fresh core or excisional biopsy of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue Histologically confirmed 25% of tumor cells expressing mesothelin as determined by NCI Laboratory of Pathology. Determination can be made using archival tumor tissue or fresh biopsy Have measurable disease based on 1.1. Lesions in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions Subjects must have received prior standard of care treatments for locally advanced or metastatic NSCLC Patients must be more than 3 weeks out of systemic treatments, such as chemotherapy All acute toxic effects of any prior radiotherapy, chemotherapy, immunotherapy, or surgical procedure must have resolved to Grade less than or equal to 1, except alopecia (any grade) and Grade 2 peripheral neuropathy Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Hypnotic Dependence Among Those With Insomnia be currently using one or more BZD or newer BzRA hypnotics at bedtime for insomnia management; 2. have been using one or more such agents at least 5 nights/week for at least the past 12 months; 3. express interest in discontinuing hypnotic use and learning to manage their insomnia without medications; 4. report one or more failed attempts to discontinue hypnotic use in the past; 5. provide written consent to participate. 6. have an insomnia severity index score > 10 indicating at least mild insomnia symptoms without sleep medication  an untreated, or unstable psychiatric disorder as suggested by current active symptoms or a medication regimen that has been changed within the past 2 months; 2. a lifetime diagnosis of any psychotic or bipolar disorder 3. an imminent risk for suicide 4. evidence of alcohol or drug abuse (other than hypnotics) within the past year, since such abuse patterns suggest specialized substance abuse treatment may be indicated 5. unstable or terminal physical illness (e.g., cancer), neurological degenerative disease (e.g., dementia) or sleep disruptive medical condition 6. current use of medications known to cause insomnia (e.g., corticosteroids) 7. screening evidence of circadian rhythm sleep disorder (e.g., delayed sleep phase syndrome) or other sleep disorder (e.g. narcolepsy, idiopathic hypersomnolence, Rapid Eye Movement (REM) behavior disorder) for which CBTI would not represent optimal therapy 8. habitual bedtimes later than 2:00 AM or rising times later than 10:00 AM; 9. consuming > 2 alcoholic beverages/day or any cannabis products at least 5 times/week 10. pregnant women or mothers with care-taking responsibilities for infants due to the sleep-disruption caused by such circumstances 11. clinical or polysomnographic evidence of undiagnosed and untreated restless legs syndrome (RLS), sleep apnea or periodic limb movements (PLMS) that require alternative therapies and would limit participants' responses to CBTI
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Pain Pelvic Pain Functional Abdominal Pain Syndrome Low Back Pain Migraine Age greater than or equal to 18 years old Diagnosis of either chronic pelvic pain, functional abdominal pain, axial low back pain, or migraine with or without aura of at least 3 months duration English speaking Ability and willingness to complete questionnaires and in-person assessments Current average daily pain score of greater than or equal to 4 on the Numeric Rating Scale of Pain (0-10 scale) For patients with migraine diagnosis they must report at least 2 headaches in the baseline headache diary in the 30 days preceding randomization  Any conditions causing inability to complete assessments (education, cognitive ability, mental status, medical status) Any significant psychiatric problems, including acute confusional state (delirium), ongoing psychosis, or clinically significant depression Any suicidality as assessed by answer of greater than 0 on question 9 the PHQ-9 assessing suicidal thoughts Any current illicit drug or alcohol abuse Any history of recurrent or unprovoked seizures Participation in another drug, device, or biologics trial concurrently or within the preceding 30 days Pregnancy, breast-feeding or lack of reliable contraception Changes in pain medications in the previous 4 weeks Implanted electrical stimulation device Skin infection over stimulation sites
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acromegaly Male or female patients, ≥18 years at screening Able to provide written informed consent to participate in the trial prior to any trial related procedures are performed Diagnosis of acromegaly by historical evidence of (persistent or recurrent) acromegaly Treatment with a stable dose of octreotide LAR or lanreotide ATG for at least 3 months as monotherapy prior to screening IGF-1 levels ≤1xULN at screening Adequate liver, pancreatic, renal and bone marrow functions Normal ECG  GH ≥2.5 μg/L at screening (cycle) Have received medical treatment for acromegaly with pasireotide (within 6 months prior to screening), pegvisomant (within 3 months prior to screening), dopamine agonists (within 3 months prior to screening) or other investigational agents (within 30 days or 5 half-lives prior to screening [whichever is longer] Patients who usually take octreotide LAR or lanreotide ATG less frequently than every 4 weeks (e.g. every 6 weeks or 8 weeks) Patients with compression of the optic chiasm causing any visual field defect for whom surgical intervention is indicated Patients who have undergone major surgery/surgical therapy for any cause within 1 month from screening Patients who have undergone pituitary surgery within 6 months prior to screening Patients who have received prior pituitary irradiation Patients with poorly controlled diabetes mellitus (hemoglobin A1c >8.0%)
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Grown-up Congenital Heart Disease (GUCH) GUCH, stable medication for at least 4 weeks  instable status, pregnancy, clinically relevant concomitant diseases, inability to follow the study procedures
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Teeth; Anomaly, Position Patients indicated for fixed appliance orthodontic treatment who have a moderate crowding (3-6mm) according to the Little's irregularity index (LII). 2. Full set of lower permanent dentition excluding the third molars. 3. No history of trauma or root resorption in the lower incisors  Previous orthodontic treatment. 2. Less than 3mm of lower incisor crowding (LII) or with spaced incisors. 3. Severe crowding in the lower arch (greater than 7mm) which requires extraction. 4. Blocked-out teeth that cannot be engaged with the aligning archwire. 5. Patients with periodontally compromised teeth
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Abdominal Pain Should be able to give informed consent for the study Has Enterra GES device in place for at least 2 months Continue to have moderate to severe abdominal pain on at least one pain questionnaire or >5 score (on a scale of 0-10 for pain) on the VAS questionnaire for at least 2 months Abdominal pain should be either persistent; for example, daily for at least >1 hour, be chronic for >2 months, and refractory to original Enterra GES settings  Unable to provide informed consent Pregnancy Any other active health problems that would render patient unable to complete the study
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 25.0-50.0,  Stress Physiology Stress, Psychological female gender to 50 years old  current or past neurological, psychiatric, and cardiac disorders cognitive impairment substance or alcohol abuse or dependence recent (last 12 months) traumatic events such as a death in the family, serious accident, job firing or divorce caregiving (last 12 months) a family member with serious pathology or disability current psychotropic or contraceptive drug use